JPMorgan Chase & Co. Boosts Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

JPMorgan Chase & Co. boosted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 135.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,278 shares of the company’s stock after buying an additional 5,915 shares during the quarter. JPMorgan Chase & Co.’s holdings in Lexeo Therapeutics were worth $93,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. BNP Paribas Financial Markets increased its stake in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares in the last quarter. Values First Advisors Inc. acquired a new position in Lexeo Therapeutics in the 3rd quarter valued at about $67,000. MetLife Investment Management LLC lifted its holdings in shares of Lexeo Therapeutics by 121.5% in the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after acquiring an additional 7,803 shares during the last quarter. PDT Partners LLC acquired a new position in shares of Lexeo Therapeutics in the 3rd quarter worth approximately $241,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Lexeo Therapeutics in the 3rd quarter worth approximately $274,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Up 3.4 %

Shares of NASDAQ LXEO opened at $5.43 on Monday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics, Inc. has a 52 week low of $4.67 and a 52 week high of $19.50. The firm has a 50-day moving average price of $6.57 and a 200 day moving average price of $8.81. The stock has a market capitalization of $179.57 million, a price-to-earnings ratio of -1.72 and a beta of 3.08.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LXEO shares. Leerink Partners reduced their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. Chardan Capital increased their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright increased their target price on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Lexeo Therapeutics has a consensus rating of “Buy” and a consensus target price of $23.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.